ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "scleroderma and systemic sclerosis"

  • Abstract Number: 814 • 2018 ACR/ARHP Annual Meeting

    NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis

    Ana Paula Luppino-Assad1, Adriana Bortoluzzo2, Henrique Carriço da Silva3, Danieli Andrade4 and Percival Sampaio-Barros4, 1Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., sao paulo, Brazil, 2c Instituto Insper de Educação e Pesquisa, São Paulo, SP, Brasil, sao paulo, Brazil, 3Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., SAO PAULO, Brazil, 4Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil

    Background/Purpose: A higher prevalence of cancer has been described in patients with systemic sclerosis (SSc), but the magnitude of this risk and the type of…
  • Abstract Number: 903 • 2018 ACR/ARHP Annual Meeting

    Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study (RISE-SSc)

    Oliver Distler1, Yannick Allanore2, Christopher P. Denton3, Masataka Kuwana4, Marco Matucci-Cerinic5, Janet E. Pope6, Janethe Pena7, Kaisa Laapas8, Zhen Yao9 and Dinesh Khanna10, 1Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Rheumatology A Department, Cochin Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France, 3UCL Division of Medicine, Royal Free Campus, London, United Kingdom, 4Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 5Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 6Department of Medicine, University of Western Ontario, London, ON, Canada, 7Clinical Development, Bayer US LLC, Whippany, NJ, 8StatFinn Oy, Espoo, Finland, 9Bayer Healthcare Co. Ltd.,, Beijing, China, 10Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI

    Background/Purpose: There are few disease-modifying therapies for the treatment of systemic sclerosis (SSc), particularly the more severe diffuse cutaneous form (dcSSc). The soluble guanylate cyclase…
  • Abstract Number: 1108 • 2018 ACR/ARHP Annual Meeting

    Antibody Repertoire Dynamics in Systemic Sclerosis after Myeloablative Autologous Hematopoietic Stem-Cell Transplantation or Cyclophosphamide Treatment

    Julia Z. Adamska1,2, Leslie Crofford3, Daniel E. Furst4,5, Ellen Goldmuntz6, Lynette Keyes-Elstein7, Maureen D. Mayes8, Peter McSweeney9, Richard Nash9, Ashley Pinckney10, Beverly Welch11, Keith Sullivan12 and William H. Robinson1,2, 1Stanford University, Stanford, CA, 2VA Palo Alto Health Care System, Palo Alto, CA, 3Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 4University of California Los Angeles, Los Angeles, CA, 5University of Washington, Seattle, WA, 6NIAID, NIH, Bethesda, MD, 7Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC, 8Rheumatology, University of Texas McGovern Medical School, Houston, TX, 9Colorado Blood Cancer Institute, Denver, CO, 10Rho Federal Systems, Inc., Chapel Hill, NC, 11National Institutes of Health, Bethesda, MD, 12Duke University Medical Center, Durham, NC

    Background/Purpose: Myeloablative autologous hematopoietic stem-cell transplantation (HSCT) was recently demonstrated to provide benefit over monthly cyclophosphamide (CYC) in the treatment of diffuse cutaneous systemic sclerosis…
  • Abstract Number: 1725 • 2018 ACR/ARHP Annual Meeting

    Fecal Microbiota Transplantation in Patients with Systemic Sclerosis- a Pilot Study

    Håvard Fretheim1, Oyvind Midtvedt1, Anders Heiervang Tennøe1, Henriette Didriksen1, Torhild Garen1, Espen Bækkevold1, Johannes R. Hov1, Knut EA Lundin2, Marius Trøseid1, Øyvind Molberg1 and Anna-Maria Hoffmann-Vold1, 1Oslo University Hospital, Oslo, Norway, 2Dept of gastroenterology, Oslo University Hospital, Oslo, Norway

    Background/Purpose: Up to 90% of patients with systemic sclerosis (SSc) have symptoms from the gastrointestinal (GI) tract. Earlier studies have shown a distinct alteration of…
  • Abstract Number: 1742 • 2018 ACR/ARHP Annual Meeting

    Disease-Specific Autoantibodies Associate with Remarkably Different Risk of Development of Significant Lung Fibrosis in Systemic Sclerosis

    Svetlana I. Nihtyanova1, Alper Sari2, Anna Leslie3, Voon H. Ong4 and Christopher P. Denton5, 1Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, 2Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 3Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, 4Division of Medicine, University College London, London, United Kingdom, 5University College London, London, United Kingdom

    Background/Purpose: Pulmonary fibrosis (PF) is a leading cause of disease-related death in SSc patients. Some studies suggest that the timing of PF development differs between…
  • Abstract Number: 1878 • 2018 ACR/ARHP Annual Meeting

    Immunosuppression in Diffuse Systemic Sclerosis Improves Outcomes Using a Novel Composite Response Index

    Boyang Zheng1, Mianbo Wang2 and Murray Baron3, 1Rheumatology, McGill University Health Center (MUHC), Montreal, QC, Canada, 2Lady Davis Institute for Medical Research, Montreal, QC, Canada, 3Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada

    Background/Purpose: Diffuse systemic sclerosis (dcSSc) is a devastating multi-organ disease where the mainstay of treatment is immunosuppression. Data on these therapies are mostly based on…
  • Abstract Number: 1879 • 2018 ACR/ARHP Annual Meeting

    The Effects of Riociguat on Raynaud’s Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study

    Dinesh Khanna1, Yannick Allanore2, Christopher P. Denton3, Masataka Kuwana4, Marco Matucci-Cerinic5, Janet E. Pope6, Janethe Pena7, Kaisa Laapas8, Zhen Yao9 and Oliver Distler10, 1Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 2Rheumatology A Department, Cochin Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France, 3UCL Division of Medicine, Royal Free Campus, London, United Kingdom, 4Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 5Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 6Department of Medicine, University of Western Ontario, London, ON, Canada, 7Clinical Development, Bayer US LLC, Whippany, NJ, 8StatFinn Oy, Espoo, Finland, 9Bayer AG, Berlin, Germany, 10Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland

    Background/Purpose: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of pulmonary arterial hypertension associated with connective tissue disease. It was anticipated that…
  • Abstract Number: 2665 • 2017 ACR/ARHP Annual Meeting

    Mortality in an Early Diffuse Cutaneous Systemic Sclerosis Cohort—Data from the Prospective Registry for Early Systemic Sclerosis

    Tracy M. Frech1, Shervin Assassi2, Elana J. Bernstein3, Flavia V. Castelino4, Robyn T. Domsic5, Jessica K. Gordon6, Faye Hant7, Monique Hinchcliff8, Bernie LaSalle9, Victoria K. Shanmugam10, Virginia D. Steen11 and Dinesh Khanna12, 1Division of Rheumatology, University of Utah, Salt Lake City, UT, 2University of Texas McGovern Medical School, Houston, TX, 3Department of Medicine, Division of Rheumatology, Columbia University, New York, NY, 4Rheumatology, Allergy, Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 5Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 6Rheumatology, Hospital for Special Surgery, New York, NY, 7Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 8Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 9University of Utah, Salt Lake City, UT, 10Rheumatology, The George Washington University, Washington, DC, 11Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, 12University of Michigan, Ann Arbor, MI

    Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS) cohort is an early diffuse cutaneous systemic sclerosis (dcSSc) that provides an opportunity to assess the…
  • Abstract Number: 2674 • 2017 ACR/ARHP Annual Meeting

    The Association between the Extent of Skin Thickness and Organ Involvement, Function and Quality of Life in Early Diffuse Cutaneous Systemic Sclerosis

    Janet E. Pope1, Murray Baron2, Tatiana Nevskaya3, Carl Baxter4 and Dena Ramey5, 1Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, 2Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, 3Rheumatology Division, St. Joseph’s Health Care London, London, ON, Canada, 4Global Outcomes Research, MSD Ltd, Hoddesdon, United Kingdom, 5Epidemiology, Merck & Co., Upper Gwynedd, PA

    Background/Purpose: To estimate whether severity of skin thickness is associated with disease severity, function, quality of life (QoL) and progression of internal organ involvement over…
  • Abstract Number: 257 • 2017 ACR/ARHP Annual Meeting

    The Use of Positron Emission Tomography (PET)-Scan for the Quantitative Assessment of Interstitial Lung Disease in Systemic Sclerosis

    Daphne Peelen1, Ben Zwezerijnen2, Esther Nossent1, Lilian Meijboom1, Otto Hoekstra3, Conny van der Laken4 and Alexandre Voskuyl4, 1VUmc, Amsterdam, Netherlands, 2Nuclear Medicine, VUmc, Amsterdam, Netherlands, 3Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, 4Department of Rheumatology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands

    Background/Purpose: Interstitial lung disease (ILD) in systemic sclerosis is treated by immunosuppressive drugs (e.g. cyclophosphamide), aimed at reduction of inflammatory response . Differentiation between inflamed…
  • Abstract Number: 2690 • 2017 ACR/ARHP Annual Meeting

    Plasma D-Dimer Levels Are More Frequently Elevated in Limited Than Diffuse Cutaneous Systemic Sclerosis but Do Not Reflect Disease Duration or Vasculopathy

    Anna Gill1, Svetlana I. Nihtyanova2, Pratima Chowdary3 and Christopher Denton1, 1Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, 2Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, 3Department of Haematology, Royal Free Hospital, London, United Kingdom

    Background/Purpose: D-dimers are degradation products of cross linked fibrin and are biomarkers of activation of the coagulation system. Plasma D-dimer levels can be raised in…
  • Abstract Number: 727 • 2017 ACR/ARHP Annual Meeting

    Survival and Clinical-Capillaroscopic Characteristics of French Canadian Systemic Sclerosis Patients: Analysis Based on Systemic Sclerosis Autoantibodies and the Novel Anti-BICD2 Autoantibody

    Boyang Zheng1, Michael Mahler2, Jean-Luc Senécal3, France Joyal4 and Martial Koenig5, 1Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada, 2Research and Development, Inova Diagnostics, San Diego, CA, 3Rheumatology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada, 4Internal Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada, 5Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada

    Background/Purpose: Systemic sclerosis (SSc) autoantibodies (aAbs) are invaluable for SSc diagnosis and prognosis. Anti-centromere (ACA), anti-topoisomerase I (ATA) and anti-RNA polymerase III (RNAP) have been…
  • Abstract Number: 2691 • 2017 ACR/ARHP Annual Meeting

    Increased Circulating Cadherin-11 Levels in Patients with Systemic Sclerosis

    Bochra Jandali1, Grace H. Lo2, Robert L. Welschhans3, Julio Charles4, Ramona Mihu3,5, Maureen D. Mayes6, Shervin Assassi7 and Sandeep K. Agarwal3, 1Medicine, Section of Immmunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, 2Immunology, Allergy, Rheumatology, Baylor College of Medicine, Houston, TX, 3Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, 4Internal Medicine/Rheumatology, University of Texas - Houston Medical School, Houston, TX, 5Medicine, Division of Rheumatology, Houston Methodist Hospital, Houston, TX, 6Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, 7University of Texas McGovern Medical School, Houston, TX

    Background/Purpose: Systemic sclerosis (SSc) is a chronic systemic disease characterized by skin and internal organs fibrosis along with vasculopathy. Previous studies have reported increased cadherin-11…
  • Abstract Number: 728 • 2017 ACR/ARHP Annual Meeting

    Symptoms of Autonomic Dysfunction in Systemic Sclerosis Assessed By the Compass-31 Questionnaire

    Brittany Adler1, James Russell2, Laura K. Hummers3 and Zsuzsanna McMahan4, 1Rheumatology, Johns Hopkins University, Baltimore, MD, 2Neurology, Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, 3Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, 4Department of Internal Medicine, Johns Hopkins University, Baltimore, MD

    Background/Purpose: Autonomic dysfunction is a known complication of systemic sclerosis (SSc) and can affect vascular tone, gastrointestinal (GI) motility, and heart rate and blood pressure…
  • Abstract Number: 2695 • 2017 ACR/ARHP Annual Meeting

    Latent Profile Analysis-Derived Typologies of Systemic Sclerosis Patients Using Body Image Indicators: A Scleroderma Patient-Centered Intervention Network (SPIN) Cohort Study

    Shadi Gholizadeh1, Linda Kwakkenbos2, Marie-Eve Carrier3, Sarah D. Mills1, Rina S. Fox4, Lisa Jewett2, Karen Gottesman5, Scott Roesch1, Brett D. Thombs2 and Vanessa L. Malcarne1, 1SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, 2McGill University; Lady David Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada, 3McGill University, Montreal, QC, Canada, 4Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, 5Scleroderma Foundation, Los Angeles, CA

    Background/Purpose: A common and distressing manifestation of systemic sclerosis (SSc, or scleroderma) is disfigurement in socially relevant areas of the body, including the face and…
  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology